TGTX - TG Therapeutics, Inc.
7.68 0.00 (0.00%)
After hours: 5:00PM EDT
| Previous Close | 7.77 |
| Open | 7.75 |
| Bid | 7.67 x 2200 |
| Ask | 7.68 x 3000 |
| Day's Range | 7.50 - 7.76 |
| 52 Week Range | 3.32 - 14.65 |
| Volume | 903,379 |
| Avg. Volume | 1,772,968 |
| Market Cap | 655.071M |
| Beta (3Y Monthly) | 1.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.14 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.67 |
- GlobeNewswire•2 days ago
TG Therapeutics to Present at the Raymond James Life Sciences and MedTech Conference
NEW YORK, June 18, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will.
- GlobeNewswire•3 days ago
TG Therapeutics Presents Preclinical Data for TG-1801, a First-in-Class Anti-CD47/CD19 Bispecific Antibody, at the 24th European Hematology Association Annual Congress
TG Therapeutics, Inc. (TGTX) today announced the presentation of preclinical data for TG-1801, the Company’s first-in-class anti-CD47/CD19 bispecific antibody, highlighting the synergistic effect of TG-1801 in combination with ublituximab, the Company’s anti-CD20 monoclonal antibody and umbralisib, the Company’s PI3K-delta inhibitor.
- GlobeNewswire•9 days ago
TG Therapeutics Confirms Registration Path for Umbralisib in Marginal Zone Lymphoma Following FDA Meeting
TG Therapeutics, Inc. (TGTX), today announced that the Company has confirmed its path to submit umbralisib for accelerated approval based on data from the marginal zone lymphoma (MZL) cohort of the UNITY-NHL Phase 2b trial. The Company recently had a productive Breakthrough Therapy Designation (BTD) meeting with the U.S. Food and Drug Administration (FDA) to discuss the MZL submission strategy.
- GlobeNewswire•16 days ago
TG Therapeutics Presents Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 55th American Society of Clinical Oncology (ASCO) Annual Meeting
TG Therapeutics, Inc. (TGTX) today presented positive interim data from the ongoing single-arm marginal zone lymphoma (MZL) cohort of its Phase 2b UNITY-NHL trial currently evaluating umbralisib as a single agent in patients with relapsed/refractory MZL. Umbralisib is an investigational, oral, once-daily PI3K delta inhibitor with unique inhibition of CK1 epsilon and is currently under development for the treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
- GlobeNewswire•16 days ago
TG Therapeutics to Present at the Jefferies 2019 Healthcare Conference
Presentation scheduled for tomorrow, Wednesday, June 5, 2019, at 9:00 AM ET NEW YORK, June 04, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S..
- TheStreet.com•23 days ago
TG Therapeutics May Have Potential but the Charts Need More Work
For his "Executive Decision" segment of Mad Money Thursday night, Jim Cramer sat down with Michael Weiss, chairman, president and CEO of TG Therapeutics Inc. Cramer noted that TGTX is a speculative company, one that still has no revenues, but their story continues to be compelling. In the daily bar chart of TGTX, below, we can see what looks like a base pattern to me when we look at volume along with the price action.
- Thomson Reuters StreetEvents•24 days ago
Edited Transcript of TGTX earnings conference call or presentation 10-May-19 12:00pm GMT
Q1 2019 TG Therapeutics Inc Earnings Call
- GlobeNewswire•last month
TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings
NEW YORK, May 16, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 55th American Society of Clinical Oncology.
Motley Fool•last monthTG Therapeutics Inc (TGTX) Q1 2019 Earnings Call Transcript
TGTX earnings call for the period ending March 31, 2019.
- Associated Press•last month
TG Therapeutics: 1Q Earnings Snapshot
On a per-share basis, the New York-based company said it had a loss of 43 cents. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•last month
TG Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results
NEW YORK, May 10, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the first quarter ended March 31, 2019 and recent company developments..
- GlobeNewswire•last month
TG Therapeutics to Host Conference Call on First Quarter 2019 Financial Results and Business Update
NEW YORK, May 09, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Friday, May 10, 2019 at 8:00 AM ET to discuss results for.
- GlobeNewswire•last month
TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71st Annual Meeting
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases, today announced the presentation of long-term follow-up data from the Phase 2 and Open Label Extension (OLE) trial of ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS). The data are being presented today at the American Academy of Neurology 71st Annual Meeting taking place in Philadelphia, PA.
- Zacks•2 months ago
Can Core MedSurg Segment Drive Stryker's (SYK) Q1 Earnings?
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine along with an upbeat 2019 view are likely to support Stryker (SYK) in Q1. But integration risks might be a dampener.
- Motley Fool•2 months ago
Is TG Therapeutics a Buy?
The stock price of this clinical-stage biotech has nearly doubled so far in 2019.
- Simply Wall St.•2 months ago
Did TG Therapeutics, Inc. (NASDAQ:TGTX) Insiders Sell Shares?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So shareholder...
- GlobeNewswire•2 months ago
TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Marginal Zone Lymphoma
TG Therapeutics, Inc. (TGTX) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to its phosphoinositide-3-kinase (PI3K) delta inhibitor, umbralisib (TGR-1202), for the treatment of patients with all three types of marginal zone lymphoma (MZL): nodal, extranodal, and splenic MZL. The MZL cohort of the UNITY-NHL trial is currently evaluating the safety and efficacy of single agent umbralisib in patients with MZL who have received at least one prior anti-CD20 regimen, the same indication for which the FDA recently granted breakthrough therapy designation for umbralisib.
- GuruFocus.com•2 months ago
5 Oncology Companies That Are Set to Run
The cancer treatment market is a massive one, and the companies that produce these treatments often make strong investment opportunities. With so much financial opportunity in the space and several areas with medical need, oncology stocks tend to be met with heavy investor interest. Warning! GuruFocus has detected 6 Warning Signs with SGEN.
- Motley Fool•2 months ago
3 Top Biotech Stocks to Buy in April
These three biotech stocks are worth buying this month.
- Investopedia•3 months ago
TG Therapeutics Breaks Out on Positive Umbralisib Data
TG Therapeutics shares moved sharply higher after positive clinical data, but traders will be watching these key levels ahead.
- Zacks•3 months ago
Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock?
Investors need to pay close attention to TG Therapeutics (TGTX) stock based on the movements in the options market lately.
- GlobeNewswire•3 months ago
TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting
Overall response rate (ORR) of 52% (N=42), with complete response (CR) rate of 19%, by central independent review committee (IRC) Responses were durable, with median duration.
- CNBC Videos•28 days ago
TG Therapeutics CEO: Going through the process to reach big markets
Jim Cramer catches up with TG Therapeutics CEO Michael Weiss in the wake of its latest earnings report.
